肝硬化患者细菌感染的全球流行病学:系统综述与Meta分析
该研究系统检索Embase、MEDLINE和Web of Science,纳入169项研究、35,180例感染患者,分析肝硬化患者细菌感染的微生物特征、耐药(AMR)模式和死亡率。革兰阳性菌占32.9%,多重耐药菌占33.3%,均有时间上升趋势;耐药比例在低收入或中低收入国家及东南亚最高,在高收入国家和美洲最低;院内、30天和90天死亡率呈时间下降趋势。
要点
- 全球肝硬化患者细菌感染中,革兰阳性菌占32.9%,呈时间上升趋势。
- 多重耐药菌占33.3%,呈上升趋势,低收入/中低收入国家和东南亚比例最高。
- 短期死亡率随时间下降,但长期死亡率下降幅度较小。
核心结论
- 肝硬化患者中革兰阳性菌和AMR相关感染增加,可能影响未来经验性抗生素策略;感染模式和耐药存在显著地域和经济差异,长期死亡率管理仍面临挑战。
研究设计与样本
- 纳入标准为报告成人肝硬化细菌感染微生物特征、AMR模式和/或死亡率的横断面研究和队列研究,无语言限制。
- 采用随机效应模型估计合并比例,并按时间段、WHO区域、世界银行收入组、感染类型和部位进行亚组分析。
主要发现
- 革兰阳性菌占所有阳性培养的32.9%(95% CI 30.3-35.5),随时间呈上升趋势,在高收入国家和欧洲比例更高。
- 多重耐药菌占阳性培养的33.3%(95% CI 28.6-38.3),呈时间上升趋势;在低收入或中低收入国家及东南亚比例最高,在高收入国家和美洲最低。
- 院内、30天和90天死亡率呈时间下降趋势,但长期死亡率下降幅度较小。
关键数值与推荐
- 革兰阳性菌占比32.9%(95% CI 30.3-35.5)。
- 多重耐药菌占比33.3%(95% CI 28.6-38.3)。
临床怎么用
- 革兰阳性菌和AMR比例上升提示需优化经验性抗生素选择。
- 地域和经济差异显著,应制定区域特异性AMR防控策略。
- 长期死亡率改善有限,需关注肝硬化感染患者的长期管理。
局限性
- 未报告具体局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The global epidemiology of bacterial infections in cirrhosis remains inadequately characterised. We aimed to delineate temporal trends and geographical variations in the microbiological profiles, antimicrobial resistance (AMR) patterns, and clinical outcomes of bacterial infections in cirrhosis. METHODS: In this systematic review and meta-analysis (PROSPERO: CRD42024593473), we searched Embase, MEDLINE and Web of Science from inception to Nov 27, 2024, without language restrictions, for cross-sectional and cohort studies reporting microbiological characteristics, AMR patterns, and/or mortality of bacterial infections in adult patients with cirrhosis. The primary outcome was the proportion of AMR among positive bacterial cultures. Secondary outcomes included bacterial distribution and mortality following bacterial infections. Pooled proportions were estimated using random-effects models, with subgroup analyses stratified by time period, World Health Organization region, World Bank income group, infection type and site. RESULTS: Of 3,891 records identified, 169 studies (35,180 infected patients) were included. Gram-positive bacteria accounted for 32.9% (95% CI 30.3-35.5) of all positive cultures, with an increasing trend over time and higher proportion observed in high-income countries and Europe. Multidrug-resistant bacteria were identified in 33.3% (95% CI 28.6-38.3) of positive cultures, with a rising temporal trend. The highest multidrug-resistant bacteria proportions were observed in low or lower-middle-income countries and in South-East Asia, and the lowest in high-income countries and the Americas. A temporal declining trend in in-hospital, 30-day, and 90-day mortality rates was observed, but the reduction was less pronounced for long-term mortality. CONCLUSION: The increase of Gram-positive and AMR-related infections may inform future empirical antibiotic strategies. Pronounced regional and economic disparities in infection patterns highlight the need for region-specific efforts to mitigate AMR. Persistent challenges remain in reducing long-term mortality. IMPACT AND IMPLICATIONS: The epidemiology of bacterial infections is critical to guide clinical and public health decision-making, yet comprehensive global data remain limited. This systematic review and meta-analysis offer a detailed global overview of microbiological profiles, antimicrobial resistance patterns, and clinical outcomes associated with bacterial infections in cirrhosis, revealing substantial temporal and geographical variations. The high proportion and growing global burden of antimicrobial resistance among patients with cirrhosis underscore the urgent need for both international collaboration and context-specific national strategies. PROSPERO REGISTRATION NUMBER: CRD42024593473.
引用
- Cai J, Yip TC, Wong GL, et al. Global epidemiology of bacterial infections in patients with cirrhosis: A systematic review and meta-analysis. J Hepatol. 2026. PMID: 41707941. doi:10.1016/j.jhep.2026.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。